[{"from": "human", "value": "Describe this molecule. [C][C@][Branch2][Ring1][Ring2][C][S][=Branch1][C][=O][=Branch1][C][=O][N][Branch1][Branch2][C][=Branch1][Ring2][=N][Ring1][Branch2][N][C][C][=C][Branch2][Ring1][=Branch2][C][=C][C][=Branch1][Ring2][=C][Ring1][=Branch1][N][C][=Branch1][C][=O][C][=N][C][=C][Branch1][Branch1][C][=C][Ring1][=Branch1][F][F]"}, {"from": "gpt", "value": "The molecule is under investigation for the treatment of Alzheimer's Disease, Prodromal Alzheimer's disease, and Amnestic Mild Cognitive Impairment.   Verubecestat is Merck\u2019s investigational oral \u03b2-site amyloid precursor protein cleaving enzyme (BACE1 or \u03b2 secretase) inhibitor. In July 2013, Merck announced positive results for Phase Ib trials of Verubecestat. In the study, administration of Verubecestat at doses of 12, 40 and 60 mg resulted in a dose-dependent and sustained reduction in the levels of Ab40, a measure of BACE1 activity, in CSF from baseline of 57, 79 and 84 percent, respectively."}]